Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19025668 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | January 2025 | April 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18967829 | Formulations of Enzalutamide | December 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18962073 | BURN WOUND TREATMENT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | No | No |
| 18950997 | CANCER TREATMENT METHOD WITH NANOCOMPOSITE | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18913776 | DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIES | October 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18911121 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | October 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18893280 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18891739 | ION CHANNEL PROSTHETIC COMPOSITIONS COMPRISING LIPID-COATED CRYSTALS OF AMPHOTERICIN B | September 2024 | May 2025 | Allow | 8 | 2 | 1 | No | No |
| 18795653 | Surfactin-Based Lipopeptide for mRNA Delivery | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18795667 | Surfactin-Based Lipopeptide for mRNA Delivery | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18778340 | SYNTHESIS AND CHARACTERIZATION OF GLAUCONITE-BASED SILICATE NANORODS AS ANTICANCER AGENT | July 2024 | October 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18765361 | MAGNETIC NANO-DRUG WITH DOUBLE TARGETING VEGF-VEGFR, AND PREPARATION METHOD AND APPLICATION THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 1 | No | No |
| 18736965 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | June 2024 | December 2024 | Allow | 6 | 1 | 1 | No | No |
| 18664867 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | May 2024 | March 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18662099 | Surfactin-Based Lipopeptide for mRNA Delivery | May 2024 | November 2024 | Allow | 6 | 1 | 1 | No | No |
| 18629707 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | April 2024 | June 2025 | Allow | 14 | 1 | 2 | Yes | No |
| 18607093 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS | March 2024 | September 2024 | Allow | 6 | 0 | 1 | No | No |
| 18429056 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | January 2024 | July 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18575043 | COMPOSITE, MANUFACTURING METHOD THEREFOR, AND COSMETIC SURGERY FILLER COMPOSITION USING SAME | December 2023 | March 2025 | Allow | 15 | 2 | 1 | No | No |
| 18390700 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18534062 | SILVER NANOPARTICLE COMPOSITION INCLUDING BIOSYNTHESIZED SILVER NANOPARTICLES AND AN EXTRACT OF FARSETIA AEGYPTIACA | December 2023 | July 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18533079 | CHITOSAN FILM WITH TERNARY METAL OXIDES | December 2023 | March 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18533083 | CHITOSAN FILM WITH TERNARY METAL OXIDES | December 2023 | March 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18501955 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | November 2023 | July 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18501950 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | November 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18501958 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | November 2023 | May 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18501945 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | November 2023 | March 2025 | Allow | 17 | 2 | 0 | No | No |
| 18384288 | Method for Synthesizing Silver Nanoparticles from Amaranthus hybridus | October 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18384214 | Method for Synthesizing Silver Nanoparticles from Amaranthus hybridus | October 2023 | June 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18481946 | PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE | October 2023 | January 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18370457 | DELIVERY SYSTEM DEVICE AND METHOD FOR PHARMACEUTICAL IMPLANTATION FOR TIMED RELEASE | September 2023 | December 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18282545 | A composition for use in the treatment of urinary or faecal incontinence | September 2023 | December 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18456719 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | August 2023 | December 2024 | Abandon | 15 | 2 | 1 | Yes | No |
| 18278416 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | August 2023 | April 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18229041 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS | August 2023 | March 2024 | Allow | 7 | 1 | 1 | No | No |
| 18357280 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | July 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18224327 | CHITOSAN FILM WITH TERNARY METAL OXIDES | July 2023 | December 2023 | Allow | 5 | 0 | 1 | No | No |
| 18223361 | ECO-FRIENDLY CONTROL OF RED PALM WEEVIL USING GREEN SYNTHESIZED SILVER NANOPARTICLES OF CHLOROPHYLL DERIVATIVES | July 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18223386 | ECO-FRIENDLY CONTROL OF RED PALM WEEVIL USING GREEN SYNTHESIZED SILVER NANOPARTICLES OF CHLOROPHYLL DERIVATIVES | July 2023 | January 2024 | Allow | 6 | 2 | 0 | No | No |
| 18341519 | LIPID PRODRUGS OF NEUROSTEROIDS | June 2023 | October 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18208435 | Method for Synthesizing Silver Nanoparticles from Amaranthus hybridus | June 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18199402 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE | May 2023 | October 2023 | Allow | 5 | 2 | 1 | No | No |
| 18313099 | HYDROGEL COMPOSITION FOR MUCOSAL LIFTING PROCEDURES WITHIN LUMENAL ANATOMICAL STRUCTURES | May 2023 | September 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18310787 | CELL OR TISSUE EMBEDDING DEVICE | May 2023 | March 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18139764 | BIODEGRADABLE BONE GLUE | April 2023 | January 2025 | Allow | 21 | 0 | 1 | No | No |
| 18137521 | BISMUTH-THIOL COMPOSITIONS AND METHODS FOR TREATING WOUNDS | April 2023 | February 2024 | Allow | 10 | 1 | 1 | No | No |
| 18134143 | ECO-FRIENDLY CONTROL OF RED PALM WEEVIL USING GREEN SYNTHESIZED SILVER NANOPARTICLES OF CHLOROPHYLL DERIVATIVES | April 2023 | September 2023 | Allow | 5 | 1 | 1 | No | No |
| 18194084 | MRNA DELIVERY COMPOSITION | March 2023 | January 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18116817 | HIGH-EFFICIENCY ANTI-TUMOR NANO-DRUG DELIVERY SYSTEM CONTAINING HYDRALAZINE AND PREPARATION METHOD THEREOF | March 2023 | July 2023 | Allow | 5 | 1 | 0 | No | No |
| 18174238 | PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF | February 2023 | December 2023 | Allow | 10 | 1 | 1 | No | No |
| 18112192 | POLYMER PARTICLES | February 2023 | June 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18165597 | DRUG-LOADED MICROBEAD COMPOSITIONS, EMBOLIZATION COMPOSITIONS AND ASSOCIATED METHODS | February 2023 | June 2025 | Allow | 28 | 0 | 1 | Yes | No |
| 18100804 | Lyophilized Compositions of Phenobarbital Sodium Salt | January 2023 | October 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18098755 | Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors | January 2023 | June 2025 | Allow | 29 | 1 | 0 | No | No |
| 18151707 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | January 2023 | June 2025 | Allow | 29 | 1 | 0 | No | No |
| 18083617 | METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1 | December 2022 | July 2025 | Allow | 30 | 1 | 1 | No | No |
| 18081546 | METHOTREXATE TREATMENT METHODS | December 2022 | December 2023 | Allow | 12 | 1 | 1 | No | No |
| 18081229 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | December 2022 | March 2025 | Allow | 27 | 0 | 1 | No | No |
| 18061725 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | December 2022 | March 2023 | Allow | 3 | 1 | 0 | No | No |
| 18073089 | Ophthalmic Drug Compositions | December 2022 | April 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18060503 | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | November 2022 | June 2023 | Allow | 7 | 0 | 1 | No | No |
| 18057842 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | November 2022 | March 2023 | Allow | 4 | 1 | 0 | No | No |
| 18057833 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | November 2022 | March 2023 | Allow | 4 | 1 | 0 | No | No |
| 17991762 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | November 2022 | March 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18056109 | HYDROGEL COMPOSITION FOR MUCOSAL LIFTING PROCEDURES WITHIN LUMENAL ANATOMICAL STRUCTURES | November 2022 | May 2023 | Allow | 6 | 0 | 1 | No | No |
| 17985235 | Formulations of Enzalutamide | November 2022 | July 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 17979033 | METHOD FOR PREPARING PHOSPHOLIPID MICELLES | November 2022 | May 2023 | Allow | 6 | 1 | 0 | No | No |
| 17979168 | OSTEOINDUCTIVE BONE IMPLANT INCLUDING HARVESTED DEMINERALIZED BONE AND BONE MORPHOGENETIC PROTEINS BOUND THERETO OBTAINED FROM THE SAME DONOR | November 2022 | April 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 17958780 | TREATMENT OF PAIN BY SUBARACHNOID ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | October 2022 | June 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17950400 | SUSTAINED-RELEASE 9-CIS RETINOIC ACID IMPLANTABLE DRUG DELIVERY PELLETS FOR THE PREVENTION OF POSTSURGICAL EDEMA AND LYMPHEDEMA | September 2022 | February 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 17932757 | NANO-SEEDING | September 2022 | March 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17943788 | Polymer Composite Nanomaterial Encapsulation System | September 2022 | May 2025 | Allow | 32 | 1 | 0 | No | No |
| 17903918 | NON-WOVEN GRAFT MATERIALS FOR NERVE REPAIR AND REGENERATION | September 2022 | October 2023 | Allow | 14 | 3 | 1 | Yes | No |
| 17892637 | LIPID-POLYMER BASED COMPLEXATION AND DELIVERY OF NUCLEIC ACIDS | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17821445 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17886773 | IMPLANT FOR OVARIAN DECLINE AND METHODS OF MANUFACTURING AN IMPLANT FOR OVARIAN DECLINE | August 2022 | April 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17819284 | GLAUCOMA TREATMENT VIA INTRACAMERAL OCULAR IMPLANTS | August 2022 | March 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17797627 | Mucoadhesive Polymeric Drug Delivery Compositions and Methods | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17879316 | MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES | August 2022 | June 2023 | Abandon | 10 | 3 | 0 | Yes | No |
| 17871428 | SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING NALTREXONE AND METHOD USING THE SAME | July 2022 | May 2023 | Allow | 9 | 2 | 0 | No | No |
| 17863068 | Coated Medical Devices and Methods of Inhibiting Implant-Associated Infections | July 2022 | June 2025 | Allow | 35 | 2 | 0 | No | No |
| 17861811 | Combination Drugs of Lachnospiraceae Bacteria and Human Immunoglobulin | July 2022 | August 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17854229 | HYDROGEL COMPOSITION, HYDROGEL BIOMEDICAL MATERIAL, METHOD FOR FACILITATING REGENERATION OF BONE AND MANUFACTURING METHOD OF HYDROGEL COMPOSITION | June 2022 | November 2024 | Allow | 29 | 0 | 1 | No | No |
| 17790426 | TREATMENT OF PAIN BY SUBARACHNOID ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | June 2022 | March 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17809717 | METHODS AND COMPOSITIONS FOR RETINAL DRUG DELIVERY | June 2022 | September 2024 | Allow | 27 | 1 | 0 | No | No |
| 17839574 | NUCLEIC ACID-SMALL DIAMETER AND LIQUID CORE NANOPARTICLE COMPLEXED COMPOSITIONS | June 2022 | May 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17835694 | NANOPARTICLES FOR TREATING PROSTATE CANCER | June 2022 | April 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17833260 | TREATMENT OF NOCTURNAL SYMPTOMS AND MORNING AKINESIA IN SUBJECTS WITH PARKINSON'S DISEASE | June 2022 | March 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17782439 | ANTI-MICROBIAL ARTICLES | June 2022 | April 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17830995 | GEL FOR TREATING PERIOCULAR AND/OR ORBITAL PATHOLOGIES AND CONDITIONS | June 2022 | February 2025 | Allow | 33 | 1 | 1 | No | No |
| 17825737 | GLYCAN MODIFIED SHORT INTERFERING RNA | May 2022 | April 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17751836 | PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF | May 2022 | January 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 17751269 | Nutraceutical Compositions TO UP-REGULATE SIRT1 and Methods of Use | May 2022 | December 2022 | Allow | 7 | 2 | 1 | No | No |
| 17744189 | METHODS OF TREATMENT WITH AN OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | May 2022 | October 2022 | Allow | 5 | 1 | 0 | No | No |
| 17736028 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | May 2022 | July 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17661215 | PHARMACEUTICAL FORMULATIONS AND SYSTEMS FOR DELIVERY OF AN ANDROGENIC AGENT AND AN AROMATASE INHIBITOR WITH SUSTAINED MULTI-PHASIC RELEASE PROFILES AND METHODS OF USE | April 2022 | July 2024 | Allow | 26 | 0 | 0 | No | No |
| 17731562 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | April 2022 | June 2023 | Allow | 13 | 3 | 1 | Yes | No |
| 17729427 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | April 2022 | February 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 17728702 | DRUG IMPLANTS CONTAINING ENZALUTAMIDE AND METHODS OF USE THEREOF | April 2022 | January 2023 | Allow | 9 | 0 | 0 | No | No |
| 17727017 | CARIPRAZINE RELEASE FORMULATIONS | April 2022 | February 2025 | Allow | 34 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AZPURU, CARLOS A.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AZPURU, CARLOS A works in Art Unit 1617 and has examined 1,209 patent applications in our dataset. With an allowance rate of 83.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.
Examiner AZPURU, CARLOS A's allowance rate of 83.0% places them in the 50% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by AZPURU, CARLOS A receive 1.51 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by AZPURU, CARLOS A is 21 months. This places the examiner in the 83% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +16.2% benefit to allowance rate for applications examined by AZPURU, CARLOS A. This interview benefit is in the 60% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 33.4% of applications are subsequently allowed. This success rate is in the 67% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 65.2% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 70.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.0% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.8% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.